Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Haque · SciRah

Researcher profile · Semantic Scholar

A. Haque

Share profile

A. Haque — researcher profile on SciRah

h-index: 19
Works: 45
Citations: 3,407

Most-cited papers

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
G. Saglio, Dong-Wook Kim, S. Issaragrisil, P. le Coutre +12 more
2010New England Journal of Medicine1,533 citations Open access
Semantic Scholar
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
H. Kantarjian, F. Giles, N. Gattermann, K. Bhalla +14 more
2007Blood769 citations Open access
Semantic Scholar
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
T. Hughes, G. Saglio, S. Branford, S. Soverini +13 more
2009Journal of Clinical Oncology343 citations Open access
Semantic Scholar
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
S. Branford, Dong-Wook Kim, S. Soverini, A. Haque +9 more
2012Journal of Clinical Oncology95 citations Open access
Semantic Scholar
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
T. Hughes, A. Hochhaus, G. Saglio, Dong-Wook Kim +11 more
201051 citations
Semantic Scholar
Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.
H. Kantarjian, F. Giles, K. Bhalla, R. Larson +6 more
200850 citations
Semantic Scholar
Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial
G. Saglio, Dong-Wook Kim, S. Issaragrisil, P. le Coutre +12 more
200941 citations
Semantic Scholar
Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
P. le Coutre, F. Giles, A. Hochhaus, J. Apperley +6 more
200840 citations
Semantic Scholar
Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
F. Giles, R. Larson, H. Kantarjian, P. le Coutre +4 more
200839 citations
Semantic Scholar
Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.
H. Kantarjian, A. Hochhaus, J. Cortes, G. Martinelli +8 more
200735 citations
Semantic Scholar
Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.
O. Ottmann, R. Larson, H. Kantarjian, P. le Coutre +4 more
200735 citations
Semantic Scholar
Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.
F. Giles, R. Larson, H. Kantarjian, P. le Coutre +4 more
200732 citations
Semantic Scholar
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
P. le Coutre, F. Giles, A. Hochhaus, J. Apperley +6 more
2009Journal of Clinical Oncology27 citations
Semantic Scholar
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).
P. le Coutre, K. Bhalla, F. Giles, M. Baccarani +7 more
200627 citations
Semantic Scholar
Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.
T. Hughes, G. Saglio, G. Martinelli, Dong-Wook Kim +8 more
200726 citations
Semantic Scholar
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
H. Kantarjian, F. J. Giles, A. Hochhaus, K. Bhalla +6 more
200823 citations
Semantic Scholar
Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)
E. Jabbour, A. Hochhaus, P. le Coutre, G. Rosti +6 more
200821 citations
Semantic Scholar
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
P. le Coutre, N. Gattermann, A. Hochhaus, R. Larson +5 more
200721 citations
Semantic Scholar
Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC).
F. Giles, P. le Coutre, K. Bhalla, G. Ossenkoppele +4 more
200720 citations
Semantic Scholar
Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).
J. Cortes, E. Jabbour, A. Hochhaus, P. le Coutre +8 more
200719 citations
Semantic Scholar
Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
E. Jabbour, H. Kantarjian, M. Baccarani, P. le Coutre +4 more
200818 citations
Semantic Scholar
Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
A. Hochhaus, Dong-Wook Kim, G. Martinelli, T. Hughes +8 more
200818 citations
Semantic Scholar
Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study
P. le Coutre, F. J. Giles, J. Apperley, Oliver G. Ottmann +6 more
200817 citations
Semantic Scholar
Functional properties and evolutionary splicing constraints on a composite exonic regulatory element of splicing in CFTR exon 12
A. Haque, E. Buratti, F. Baralle
2009Nucleic Acids Research16 citations Open access
Semantic Scholar
Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.
P. le Coutre, F. Giles, J. Apperley, O. Ottmann +9 more
200715 citations Open access
Semantic Scholar
Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).
A. Hochhaus, G. Saglio, R. Larson, Dong-Wook Kim +11 more
201012 citations
Semantic Scholar
Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study
E. Abruzzese, G. Alimena, P. le Coutre, K. Bhalla +5 more
20089 citations
Semantic Scholar
Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.
G. Saglio, Dong-Wook Kim, A. Hochhaus, S. Soverini +8 more
20078 citations
Semantic Scholar
Clinical Profile of Acute Pancreatitis in Children in a Tertiary Level Hospital of Bangladesh
N. Musabbir, A. Karim, Wahiduzzaman Mazumder, K. Sultana +3 more
20177 citations Open access
Semantic Scholar
Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study
F. Giles, P. le Coutre, K. Bhalla, G. Ossenkoppele +4 more
20087 citations
Semantic Scholar
Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP)
E. Jabbour, P. le Coutre, M. Baccarani, K. Bhalla +6 more
20077 citations
Semantic Scholar
Urinary Tract Infection due to Extended-Spectrum Beta-Lactamase Producing Organisms is a Risk Factor for Acute Kidney Injury among Patients with Type 2 Diabetes Mellitus
M. Rahim, P. Mitra, A. Haque, S. Zaman +8 more
20176 citations Open access
Semantic Scholar
Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
S. Branford, Dong-Wook Kim, S. Soverini, E. Gottardi +11 more
20096 citations
Semantic Scholar
Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
J. Radich, G. Martinelli, A. Hochhaus, E. Gottardi +11 more
20096 citations
Semantic Scholar
Mutation detection sensitivity of high resolution melting in clinical samples: a comparative study between formamide and dimethyl sulfoxide
Dipa Roy, Md. Mahmudul Hasan, A. Haque
2019Journal of Advanced Biotechnology and Experimental Therapeutics3 citations Open access
Semantic Scholar
Identification and Frequency of Causative Organism in Oral Candidiasis in Early Childhood in Bangladesh
A. Parvin, Dipa Roy, Nur-E-saud, A. Awal +2 more
2022Acta Scientific Dental Scienecs2 citations Open access
Semantic Scholar
Identification of TNF-Þ-308G/A (rsl800629) polymorphism in Bangladeshi population related to type-2 diabetes
Dipa Roy, Sk Shahid Ullah, B. Basak, M. Hasan +2 more
2019Journal of Applied Biology & Biotechnology1 citations Open access
Semantic Scholar
Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
A. Hochhaus, G. Saglio, H. Kantarjian, A. Haque +6 more
20101 citations
Semantic Scholar
A case report of a successfully treated patient of granulomatosis with polyangitis and diabetes mellitus
Tasnova Mahin, A. Haque, T. Samad, M. Rahim +1 more
2022BIRDEM Medical Journal0 citations Open access
Semantic Scholar
Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma
Md. Zillur Rahman Bhuiyan, R. Sultana, Ranjan Kumar Bhoumic, Sayed Farhan Ali Razib +2 more
2021Cancer research journal0 citations Open access
Semantic Scholar
Tumor necrosis factor-alpha 308G>A polymorphism cause coronary heart disease in type-2 diabetic patients of the northern region of Bangladesh
Md Mahmud, M. Hasan, Dipa Roy, M. Ullah +3 more
2021Journal of Advanced Biotechnology and Experimental Therapeutics0 citations Open access
Semantic Scholar
Prevalence of single-nucleotide polymorphism (-308G>A) in the TNF-α promoter region correlates coronary heart disease among type-2 diabetic patients from the northern region of Bangladesh
Md. Rezuan Al Mahmud, M. Hasan, Dipa Roy, Md. Sk. Shahid Ullah +4 more
20200 citations
Semantic Scholar
RESCUE OF REFRACTORY SPLICING OF CFTR EXON 12 PATHOLOGICAL MUTATIONS G576A/G48C USING ANTISENSE OLIGONUCLEOTIDES
A. Haque
20110 citations Open access
Semantic Scholar
Characterisation of a Composite Exonic Regulatory Element of Splicing (CERES) in CFTR Exon 12: Functional Properties and Evolutionary Constraints
A. Haque
20100 citations
Semantic Scholar
Response and outcomes to nilotinib at 24 months in patients with imatinib-resistant chronic myeloid leukemia in chronic phase and accelerated phase with and without BCR-ABL mutations
J. Radich, G. Martinelli, A. Hochhaus, E. Gottardi +11 more
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Kantarjian×28
Invite
H. Kantarjian — researcher profile on SciRah
P. le Coutre×23
Invite
P. le Coutre — researcher profile on SciRah
N. Gallagher×23
Invite
N. Gallagher — researcher profile on SciRah
A. Hochhaus×19
Invite
A. Hochhaus — researcher profile on SciRah

×16

Invite

F. Giles — researcher profile on SciRah

Invite

G. Saglio — researcher profile on SciRah

Dong-Wook Kim×13

Invite

Dong-Wook Kim — researcher profile on SciRah

Invite

T. Hughes — researcher profile on SciRah

Invite

R. Larson — researcher profile on SciRah

Invite

K. Bhalla — researcher profile on SciRah

G. Ossenkoppele×11

Invite

G. Ossenkoppele — researcher profile on SciRah

Invite

Y. Shou — researcher profile on SciRah